Abstracts tagged "giant cell arteritis"

Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Francisco Javier Narváez³, Elena Aurrecoechea⁴, Ignacio Villa-Blanco⁵, Santos Castañeda⁶, Catalina Gómez-Arango⁷, Antonio Mera⁸, Eva Perez Pampín⁸, Vicente Aldasoro⁹, Noelia Álvarez-Rivas¹⁰, Nagore Fernandez-Llanio Cornella¹¹, Maria Concepcion Alvarez de Buergo¹², Luisa Marena Rojas Vargas¹³, Francisca Sivera¹⁴, Eva Galindez-Agirregoikoa¹⁵, Roser Solans¹⁶, Susana Romero-Yuste¹⁷, Norberto Ortego Centeno¹⁸, Marcelino Revenga Martínez¹⁹, Rafael Melero²⁰, Eva Salgado-Pérez²¹, Sabela Fernández²², José Luis Martín-Varillas²³, Isabel Martínez-Rodríguez²⁴, Ignacio Banzo²⁴, Vanesa Calvo-Río²³, Belén Atienza-Mateo²³, Natalia Palmou-Fontana²³, Carmen González-Vela²⁵, José Luis Hernández², Miguel Angel González-Gay²³ and Ricardo Blanco²³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ⁴Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ⁸Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁹Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ¹⁰Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹¹Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ¹²Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹³Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ¹⁴Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁵Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ¹⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ¹⁸Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁹Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ²⁰Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ²¹Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ²²Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²⁴Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…
Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Monica Calderón Goercke¹, Diana Prieto Peña¹, Javier Loricera², Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁴, Clara Moriano Morales⁶, Susana Romero-Yuste⁷, Francisco Javier Narváez⁸, Catalina Gómez-Arango⁹, Eva Perez Pampín¹⁰, Rafael Melero¹¹, Elena Becerra-Fernández¹², Marcelino Revenga Martínez¹³, Noelia Álvarez-Rivas¹⁴, Carlos Galisteo¹⁵, Francisca Sivera¹⁶, Alejandro Olivé-Marqués¹⁷, Maria Concepcion Alvarez de Buergo¹⁸, Luisa Marena Rojas Vargas¹⁹, Carlos Fernandez-Lopez²⁰, Francisco Navarro²¹, Enrique Raya Álvarez²², Eva Galindez-Agirregoikoa²³, Beatriz Arca²⁴, Roser Solans²⁵, Arantxa Conesa²⁶, Cristina Hidalgo-Calleja²⁷, Carlos Vázquez²⁸, Pau Lluch²⁹, Jose Andrés Román Ivorra³⁰, Sara Manrique-Arija³¹, Paloma Vela³², Eugenio De Miguel³³, Carmen Torres-Martín³⁴, Juan Carlos Nieto³⁵, Carmen Ordas-Calvo³⁶, Eva Salgado-Pérez³⁷, Cristina Luna Gómez³⁸, Francisco J. Toyos Sáenz de Miera³⁹, Nagore Fernandez-Llanio Cornella⁴⁰, Antonio García⁴¹, Carmen Larena⁴², Belén Atienza-Mateo⁴³, José Luis Martín-Varillas⁴³, Natalia Palmou-Fontana⁴³, Vanesa Calvo-Río⁴³, Carmen González-Vela⁴⁴, Alfonso Corrales⁴³, María Varela-García⁴⁵, Elena Aurrecoechea⁴⁶, Raquel Dos Santos⁴⁷, Angel García-Manzanares¹², Norberto Ortego Centeno⁴⁸, Sabela Fernández⁴⁹, Francisco Ortiz-Sanjuán⁵⁰, Montserrat Corteguera³⁴, Miguel Angel González-Gay⁴³, José Luis Hernández² and Ricardo Blanco⁴³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ⁸Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ⁹Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹⁰Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹¹Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹²Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹³Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁴Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁵Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁶Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹⁹Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²⁰Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²¹Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²²Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²⁴Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁵Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁶Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁸Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ²⁹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³⁰Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Medicine, University of Málaga, MÁLAGA, Spain, ³²Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³³Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁴Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁶Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁷Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁸Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ³⁹Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴⁰Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴¹Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁴Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁵Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁶Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁷Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁸Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴⁹Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ⁵⁰Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain
Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…
Abstract Number: 2755 • 2018 ACR/ARHP Annual Meeting
Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Clara Moriano Morales³, Elvira Diez Alvarez⁴, Francisco Javier Narváez⁵, Antonio Mera⁶, Eva Perez Pampín⁶, Vicente Aldasoro⁷, María Varela-García⁸, Noelia Álvarez-Rivas⁹, Ceferino Barbazan¹⁰, Carmen Ordas-Calvo¹¹, Francisca Sivera¹², Cristina Luna Gómez¹³, Francisco J. Toyos Sáenz de Miera¹⁴, Arantxa Conesa¹⁵, Francisco Navarro¹⁶, Belén Atienza-Mateo¹⁷, José Luis Martín-Varillas¹⁷, Eva Galindez-Agirregoikoa¹⁸, Vanesa Calvo-Río¹⁷, Carmen González-Vela¹⁹, Natalia Palmou-Fontana², José Luis Hernández², Miguel Angel González-Gay² and Ricardo Blanco¹⁷, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ⁶Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁷Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁸Complejo Hospitalario de Navarra, Navarra, Spain, ⁹Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹¹Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ¹²Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹³Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ¹⁴Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ¹⁵Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ¹⁶Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ¹⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, University Hospital of Basurto, Bilbao, Spain, ¹⁹Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a special predilection for extracranial branches of the external carotid artery. Among its most…
Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Sebastian H. Unizony¹, Jinglan Pei², Páris N. Sidiropoulos², Jennie H. Best², Christine Birchwood² and John H. Stone³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting
High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort
Sarah H. Chung¹, Meredith B. Morcos¹ and Bernard Ng^1,2, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 791 • 2017 ACR/ARHP Annual Meeting
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Filippo Crescentini¹, Francesco Muratore², Lucia Spaggiari³, Giulia Pazzola¹, Luigi Boiardi¹, Nicolò Pipitone¹ and Carlo Salvarani⁴, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ³Radiology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy
Background/Purpose: To evaluate aortic diameter and predictors of aortic dilatation using FDG-PET/CT in a longitudinally followed cohort of patients with large vessel vasculitis (LVV) compared…
Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Ignacio Castaño¹, Irene Monjo², Alejandro Balsa³, Diana Peiteado², Sara García-Carazo⁴ and Eugenio De Miguel¹, ¹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²Rheumatology, Hospital Universitario La Paz, MADRID, Spain, ³Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 796 • 2017 ACR/ARHP Annual Meeting
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Laure Delaval^1,2, Aurélie Daumas³, Maxime Samson⁴, Mikael Ebbo⁵, Hubert de Boysson⁶, Eric Liozon⁷, Henry Dupuy⁸, Alexis Regent⁹, Mathieu Puyade¹⁰, Daniel Blockmans¹¹, Estibaliz Lazaro¹², Ygal Benhamou¹³, Karim Sacre¹⁴, Alice Bérezné¹⁵, Loïc Guillevin^2,9,16 and Benjamin Terrier^17,18,19, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Marseille, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵internal medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Paris, France, ⁶Department of Internal Medicine, Caen University Hospital, Caen, France, ⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁰Department of Internal Medicine, University Hospital of Poitiers, Poitiers, France, ¹¹General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ¹²Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, ¹³Department of internal medicine, University Hospital of Rouen, Rouen, France, ¹⁴Department of Internal Medicine, Bichat Hospital, Paris, France, ¹⁵Department of internal medicine, CHR Annecy-Genevois, Metz-Tessy, France, ¹⁶French Vasculitis Study Group (FVSG), Paris, France, ¹⁷Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹French Vasculitis Study Group (FVSG), paris, France
Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA.…
Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Laure Delaval^1,2, Maxime Samson³, Flora Schein⁴, Christian Agard⁵, Olivier Aumaître⁶, Alban Deroux⁷, Henry Dupuy⁸, Cyril Garrouste⁹, cedric landron¹⁰, Francois Maurier¹¹, Pascal Cathebras¹², Loïc Guillevin^2,13,14 and Benjamin Terrier^15,16,17, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Internal medicine, University Hospital St Etienne, Saint Etienne, France, ⁵Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, CHU de Grenoble, Grenoble, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹²Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹³French Vasculitis Study Group (FVSG), Paris, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁶French Vasculitis Study Group (FVSG), paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…
Abstract Number: 259 • 2017 ACR/ARHP Annual Meeting
Imaging for Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Review of the Literature and Meta-Analysis Informing the EULAR Recommendations
Christina Duftner¹, Christian Dejaco², Alexandre Sepriano³, Louise Falzon⁴, Wolfgang A. Schmidt⁵ and Sofia Ramiro⁶, ¹Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ²Rheumatology, Hospital of Bruneck, Bruneck, Italy, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY, ⁵Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: Modern imaging techniques including ultrasound (US), magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET) are increasingly studied in large…
Abstract Number: 799 • 2017 ACR/ARHP Annual Meeting
Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Philip Therkildsen¹, Berit Dalsgaard Nielsen¹, Kresten Krarup Keller², Torben Steiniche³, Lars Christian Gormsen⁴, Ib Tønder Hansen⁵ and Ellen-Margrete Hauge⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Histopathology, Aarhus University Hospital, Aarhus C, Denmark, ⁴Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The temporal artery biopsy (TAB) remains the gold standard in the diagnosis of giant cell arteritis (GCA). However, TABs are false-negative in 40% of…
Abstract Number: 261 • 2017 ACR/ARHP Annual Meeting
Ultrasound CUT-Off in GIANT CELL Arteritis a Solution to Arteriosclerosis Pitfall in the Halo Sign
Eugenio De Miguel¹, Luis M Beltran², Irene Monjo², Francesco Deodati², Wolfgang A. Schmidt³ and Juan García-Puig², ¹Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ²Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ³Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: At the age of Giant Cell Arteritis (GCA) atherosclerosis is common. The ultrasonographic (US) appearance of athermanous plaque is usually easily differentiated from the…
Abstract Number: 805 • 2017 ACR/ARHP Annual Meeting
Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Andrea Gloor¹, Daniel Yerly², Stefan Kuchen³, Sabine Adler⁴, Stephan Reichenbach¹, Michael Seitz⁵ and Peter M. Villiger⁶, ¹Rheumatology, University hospital, Bern, Switzerland, ²Rheumatology, Uiversity hospital, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland, ⁴Rheumatology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology & Allergology, University Hospital, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) about tocilizumab (TCZ) in giant cell arteritis (GCA) showed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].